These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 29705709)
1. Design, synthesis and structure-activity relationship studies of GPR40 agonists containing amide linker. Chen T; Ning M; Ye Y; Wang K; Leng Y; Shen J Eur J Med Chem; 2018 May; 152():175-194. PubMed ID: 29705709 [TBL] [Abstract][Full Text] [Related]
2. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470). Hamdouchi C; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Eessalu TE; Ficorilli JV; Marcelo MC; Otto KA; Wilbur KL; Lineswala JP; Piper JL; Coffey DS; Sweetana SA; Haas JV; Brooks DA; Pratt EJ; Belin RM; Deeg MA; Ma X; Cannady EA; Johnson JT; Yumibe NP; Chen Q; Maiti P; Montrose-Rafizadeh C; Chen Y; Reifel Miller A J Med Chem; 2016 Dec; 59(24):10891-10916. PubMed ID: 27749056 [TBL] [Abstract][Full Text] [Related]
3. Polar aromatic periphery increases agonist potency of spirocyclic free fatty acid receptor (GPR40) agonists inspired by LY2881835. Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Golovanov A; Zozulya S; Zahanich I; Moore D; Tikhonova IG Eur J Med Chem; 2017 Feb; 127():357-368. PubMed ID: 28076825 [TBL] [Abstract][Full Text] [Related]
4. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold. Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660 [TBL] [Abstract][Full Text] [Related]
5. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus. Rani L; Grewal AS; Sharma N; Singh S Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel GPR40 agonists. Jiang XW; Jiang BE; Liu H; Liu ZT; Hu LL; Liu M; Lu W; Zhang HK Eur J Med Chem; 2018 Oct; 158():123-133. PubMed ID: 30212763 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold. Li Z; Liu C; Yang J; Zhou J; Ye Z; Feng D; Yue N; Tong J; Huang W; Qian H Eur J Med Chem; 2019 Oct; 179():608-622. PubMed ID: 31279294 [TBL] [Abstract][Full Text] [Related]
9. Discovery of novel free fatty acid receptor 1 agonists bearing triazole core via click chemistry. Li Z; Yang J; Wang X; Li H; Liu C; Wang N; Huang W; Qian H Bioorg Med Chem; 2016 Nov; 24(21):5449-5454. PubMed ID: 27624524 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes. Li Z; Qiu Q; Xu X; Wang X; Jiao L; Su X; Pan M; Huang W; Qian H Eur J Med Chem; 2016 May; 113():246-57. PubMed ID: 26945112 [TBL] [Abstract][Full Text] [Related]
11. Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold. Krasavin M; Lukin A; Zhurilo N; Kovalenko A; Zahanich I; Zozulya S; Moore D; Tikhonova IG Bioorg Med Chem; 2016 Jul; 24(13):2954-2963. PubMed ID: 27229618 [TBL] [Abstract][Full Text] [Related]
12. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges. Li Z; Xu X; Huang W; Qian H Med Res Rev; 2018 Mar; 38(2):381-425. PubMed ID: 28328012 [TBL] [Abstract][Full Text] [Related]
13. Discovery of new dual PPARγ-GPR40 agonists with robust antidiabetic activity: Design, synthesis and in combo drug evaluation. Hidalgo-Figueroa S; Navarrete-Vázquez G; Estrada-Soto S; Giles-Rivas D; Alarcón-Aguilar FJ; León-Rivera I; Giacoman-Martínez A; Miranda Pérez E; Almanza-Pérez JC Biomed Pharmacother; 2017 Jun; 90():53-61. PubMed ID: 28342366 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ. Li Z; Zhou Z; Deng F; Li Y; Zhang D; Zhang L Eur J Med Chem; 2018 Nov; 159():267-276. PubMed ID: 30296685 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents. Li Z; Hu L; Wang X; Zhou Z; Deng L; Xu Y; Zhang L Bioorg Chem; 2019 Nov; 92():103254. PubMed ID: 31518760 [TBL] [Abstract][Full Text] [Related]
16. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space. Chen C; Li H; Long YQ Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762 [TBL] [Abstract][Full Text] [Related]
17. Recent Advances in Development of GPR40 Modulators (FFA1/FFAR1): An Emerging Target for Type 2 Diabetes. Sharma N; Bhagat S; Chundawat TS Mini Rev Med Chem; 2017; 17(11):947-958. PubMed ID: 28117025 [TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of novel and potent GPR119 agonists with a spirocyclic structure. Harada K; Mizukami J; Kadowaki S; Matsuda I; Watanabe T; Oe Y; Kodama Y; Aoki K; Suwa K; Fukuda S; Yata S; Inaba T Bioorg Med Chem Lett; 2018 Apr; 28(7):1228-1233. PubMed ID: 29519733 [TBL] [Abstract][Full Text] [Related]
19. Discovery of novel selective GPR120 agonists with potent anti-diabetic activity by hybrid design. Sheng R; Yang L; Zhang Y; Xing E; Shi R; Wen X; Wang H; Sun H Bioorg Med Chem Lett; 2018 Aug; 28(15):2599-2604. PubMed ID: 29980358 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and structure-activity relationship studies of novel free fatty acid receptor 1 agonists bearing amide linker. Yang J; Li Z; Li H; Liu C; Wang N; Shi W; Liao C; Cai X; Huang W; Qian H Bioorg Med Chem; 2017 Apr; 25(8):2445-2450. PubMed ID: 28285923 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]